Видео ютуба по тегу Cardiol Therapeutics

Discussion with David Elsley | Cardiol Therapeutics (NASDAQ:CRDL)
Discussion with David Elsley | Cardiol Therapeutics (NASDAQ:CRDL)
Cardiol Therapeutics CEO on CardiolRx, Clinical Trials & Orphan Drug Status
Cardiol Therapeutics CEO on CardiolRx, Clinical Trials & Orphan Drug Status
A Medical Breakthrough the Market Overlooked | David Elsley - Cardiol Therapeutics
A Medical Breakthrough the Market Overlooked | David Elsley - Cardiol Therapeutics
𝗖𝗔𝗥𝗗𝗜𝗢𝗟 𝗧𝗛𝗘𝗥𝗔𝗣𝗘𝗨𝗧𝗜𝗖𝗦 (𝗖𝗥𝗗𝗟) 𝗦𝗢𝗔𝗥𝗦 𝗢𝗡 𝗣𝗛𝗔𝗦𝗘 𝗜𝗜 𝗠𝗬𝗢𝗖𝗔𝗥𝗗𝗜𝗧𝗜𝗦 𝗕𝗥𝗘𝗔𝗞𝗧𝗛𝗥𝗢𝗨𝗚𝗛 | 𝗜𝗡𝗩𝗘𝗦𝗧𝗢𝗥 𝗨𝗣𝗗𝗔𝗧𝗘
𝗖𝗔𝗥𝗗𝗜𝗢𝗟 𝗧𝗛𝗘𝗥𝗔𝗣𝗘𝗨𝗧𝗜𝗖𝗦 (𝗖𝗥𝗗𝗟) 𝗦𝗢𝗔𝗥𝗦 𝗢𝗡 𝗣𝗛𝗔𝗦𝗘 𝗜𝗜 𝗠𝗬𝗢𝗖𝗔𝗥𝗗𝗜𝗧𝗜𝗦 𝗕𝗥𝗘𝗔𝗞𝗧𝗛𝗥𝗢𝗨𝗚𝗛 | 𝗜𝗡𝗩𝗘𝗦𝗧𝗢𝗥 𝗨𝗣𝗗𝗔𝗧𝗘
Cardiol Therapeutics gets FDA go ahead for Investigational New Drug Application for CardiolRx
Cardiol Therapeutics gets FDA go ahead for Investigational New Drug Application for CardiolRx
Cardiol Therapeutics starts Health Canada approved Phase 1 clinical study of CardiolRx
Cardiol Therapeutics starts Health Canada approved Phase 1 clinical study of CardiolRx
Cardiol Therapeutics enrols first patient in Phase 2 study of CardiolRx for Recurrent Pericarditis
Cardiol Therapeutics enrols first patient in Phase 2 study of CardiolRx for Recurrent Pericarditis
A Heart Disease Cure for Pericarditis? Phase 3 Trial Advances | David Elsley - Cardiol Therapeutics
A Heart Disease Cure for Pericarditis? Phase 3 Trial Advances | David Elsley - Cardiol Therapeutics
Significant LV Mass Impact Seen in ARCHER Trial - Full Data to be released at Cardiology Forum
Significant LV Mass Impact Seen in ARCHER Trial - Full Data to be released at Cardiology Forum
Cardiol Therapeutics is Working to Curing Myocarditis
Cardiol Therapeutics is Working to Curing Myocarditis
Cardiol Therapeutics commences Phase II study of CardiolRx for treatment of Recurrent Pericarditis
Cardiol Therapeutics commences Phase II study of CardiolRx for treatment of Recurrent Pericarditis
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)
Cardiol Therapeutics Receives FDA Orphan Drug Designation for Pericarditis Treatment
Cardiol Therapeutics Receives FDA Orphan Drug Designation for Pericarditis Treatment
Cardiol Therapeutics releases positive study results of subcutaneously administered cannabidiol
Cardiol Therapeutics releases positive study results of subcutaneously administered cannabidiol
Cardiol Therapeutics signs supply agreement with Medical Cannabis by Shoppers
Cardiol Therapeutics signs supply agreement with Medical Cannabis by Shoppers
10. IIF - Cardiol Therapeutics Inc., David Elsley, CEO, on Myocarditis, Pericarditis and Orphan-Drug
10. IIF - Cardiol Therapeutics Inc., David Elsley, CEO, on Myocarditis, Pericarditis and Orphan-Drug
Cardiol Therapeutics (CRDL) - David Elsley, President and CEO
Cardiol Therapeutics (CRDL) - David Elsley, President and CEO
Game-Changing Solution for Heart Inflammation? | David Elsley - Cardiol Therapeutics
Game-Changing Solution for Heart Inflammation? | David Elsley - Cardiol Therapeutics
Cardiol Therapeutics, Inc. - CardiolRx™ Phase II & III Outcomes Study
Cardiol Therapeutics, Inc. - CardiolRx™ Phase II & III Outcomes Study
David Elsley, President & CEO, Cardiol Therapeutics Inc.
David Elsley, President & CEO, Cardiol Therapeutics Inc.
Cardiol Therapeutics - CBD Advantages Over Steroids As Anti-Inflammatory Therapy For Heart Disease
Cardiol Therapeutics - CBD Advantages Over Steroids As Anti-Inflammatory Therapy For Heart Disease
Cardiol $CRDL Lists On NASDAQ With FDA Approved Clinical Trials & $50,000,000 Raised Last 12 Months
Cardiol $CRDL Lists On NASDAQ With FDA Approved Clinical Trials & $50,000,000 Raised Last 12 Months
AGORACOM Small Cap 60: Cardiol Therapeutics $CRDL $CRTPF -
AGORACOM Small Cap 60: Cardiol Therapeutics $CRDL $CRTPF - "The Cannabidiols Pharmaceutical Process"
4. IIF - Cardiol Therapeutics Inc.
4. IIF - Cardiol Therapeutics Inc.